← Back to headlines
Merck and Eisai's Keytruda Regimen Fails Late-Stage Kidney Cancer Trial
Pharmaceutical companies Merck and Eisai have encountered a setback in a late-stage clinical trial for their Keytruda regimen, intended for the treatment of kidney cancer.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
